Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy

Megan Crane, Anchalee Avihingsanon, Reena Rajasuriar, Pushparaj Velayudham, David Iser, Ajantha Solomon, Baotuti Sebolao, Andrew Tran, Tim Spelman, Gail Matthews, Paul Cameron, Pisit Tangkijvanich, Gregory J. Dore, Kiat Ruxrungtham, Sharon R. Lewin

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor α, and interferon γ (IFN-γ) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-γ and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.

Original languageEnglish
Pages (from-to)745-751
Number of pages7
JournalJournal of Infectious Diseases
Volume210
Issue number5
DOIs
StatePublished - 1 Sep 2014
Externally publishedYes

Keywords

  • Fibrosis
  • HIV/HBV coinfection
  • Microbial translocation

Fingerprint

Dive into the research topics of 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy'. Together they form a unique fingerprint.

Cite this